Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2951 to 3000 of 3803 results for treatment

  1. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    augmented (step-down) care in community mental health services versus treatment as usual to determine whether the gains of early...

    Research recommendation
    Published
    9 June 2015

  2. What is the clinical effectiveness of preoperative nasal decolonisation using mupirocin in combination with a chlorhexidine body wash in the whole population?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    16 August 2019

  3. What is the effectiveness of decolonisation using alternative interventions in combination with nasal decolonisation in the prevention of surgical site infections when chlorhexidine is contraindicated?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  4. What is the clinical and cost effectiveness of a double application of antiseptic to the skin at the surgical site compared with a single application?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  5. What is the clinical and cost effectiveness of different modes of applying skin antiseptic before incision in the prevention of surgical site infection?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

    Research recommendation
    Published
    26 October 2020

  6. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    Source guidance details Comes from guidance Mifamurtide for the treatment of osteosarcoma Number TA235 Date issued October 2011

    Research recommendation
    Published
    9 June 2015

  7. Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)

    We have moved interventional procedures guidance 205 to become HealthTech guidance 131. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults (IPG693)

    We have moved interventional procedures guidance 693 to become HealthTech guidance 577. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)

    RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

  10. Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil at the higher dose used in the Chronic Lymphocytic Leukaemia Trial 4 (CLL4).

    details Comes from guidance Bendamustine for the first-line treatment of chronic lymphocytic leukaemia Number TA216 Date issued

    Research recommendation
    Published
    9 June 2015

  11. Antibiotics for suspected early-onset infection: What is the incidence and severity of adverse effects with antibiotics used to prevent or treat early-onset neonatal infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  12. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    guidance Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued

    Research recommendation
    Published
    9 June 2015

  13. The effectiveness of pulsatile gonadotrophin-releasing hormone in women with clomifene citrate-resistant polycystic ovary syndrome is uncertain and is therefore not recommended outside a research context. [2004]

    details Comes from guidance Fertility problems: assessment and treatment Number CG156 Date issued February 2013 Other

    Research recommendation
    Published
    9 June 2015

  14. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Number TA217 Date issued March

    Research recommendation
    Published
    9 June 2015

  15. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Withdrawn guidance

  16. Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy to adults, young people and children with asthma that is uncontrolled on a moderate dose of ICS plus LABA with or without LTRA?

    LAMA is not cost effective compared with treatment with a placebo. In current practice, the alternative treatment options...

    Research recommendation
    Published
    18 October 2018

  17. Antibiotics for suspected early-onset infection: What is the incidence in England and Wales of resistance to commonly used antibiotics among bacteria that cause early-onset neonatal infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  18. Information and support: What is the clinical and cost effectiveness of information and support offered to parents and carers of babies who have received antibiotics for suspected or proven early-onset neonatal infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  19. Antibiotics for suspected early-onset infection: What are the core exposures and outcomes that should be used to evaluate clinical effectiveness of antibiotics to prevent or treat early- onset neonatal infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  20. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    guidance Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued

    Research recommendation
    Published
    9 June 2015

  21. Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be conducted.

    Source guidance details Comes from guidance Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein...

    Research recommendation
    Published
    9 June 2015

  22. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

    HealthTech guidance
    Published
    4 December 2025
    View recommendations

    Sections for HTG761

  23. Further collection of quality of life data from people who are cured and who have experience of amputation and chemotherapy are also needed. Additional data on the health effects on parents, siblings and others with life-threatening illness would also be of value.

    Source guidance details Comes from guidance Mifamurtide for the treatment of osteosarcoma Number TA235 Date issued October 2011

    Research recommendation
    Published
    9 June 2015

  24. Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

    guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Number TA217 Date issued March

    Research recommendation
    Published
    9 June 2015

  25. People who are concerned about their fertility should be informed that the effectiveness of complementary therapies for fertility problems has not been properly evaluated and that further research is needed before such interventions can be recommended. [2004]

    details Comes from guidance Fertility problems: assessment and treatment Number CG156 Date issued February 2013 Other

    Research recommendation
    Published
    9 June 2015

  26. Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

    Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

    Medtech innovation briefing
    Published
    28 June 2016

  27. A trial comparing the long-term effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be beneficial. It should collect utility data as well as walking distance outcomes.

    naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral...

    Research recommendation
    Published
    9 June 2015

  28. The Committee recommends that a study estimating utility values using directly observed health-related quality of life values (such as EQ 5D scores) in patients with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia is conducted.

    Source guidance details Comes from guidance Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia...

    Research recommendation
    Published
    9 June 2015

  29. The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.

    guidance details Comes from guidance Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior...

    Research recommendation
    Published
    25 October 2019

  30. Investigations for babies who may have early-onset infection: What is the clinical and cost effectiveness of laboratory investigations used individually or in combination to exclude early-onset neonatal infection in babies receiving antibiotics for suspected infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  31. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  32. What is the effect of dietary interventions or dietary changes on acne?

    committee's discussion are in evidence review C: dietary interventions for the treatment of acne vulgaris. Source guidance details Comes...

    Research recommendation
    Published
    3 May 2024

  33. Diet: What is the effect of dietary interventions or dietary changes on acne?

    committee's discussion are in evidence review C: dietary interventions for the treatment of acne vulgaris. Source guidance details Comes...

    Research recommendation
    Published
    10 August 2021

  34. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  35. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTG746)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.

    HealthTech guidance
    Last updated
    17 March 2026
    View recommendations

    Sections for HTG746

  36. Complex PTSD:- What is the clinical and cost effectiveness of interventions to deliver stabilisation and reintegration for people with complex PTSD?

    psychological, psychosocial and other non-pharmacological interventions for the treatment of PTSD in adults. Source guidance details...

    Research recommendation
    Published
    13 February 2019

  37. Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women with meconium-stained amniotic fluid?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  38. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    about how this affects cost of the quality of life of patients receiving treatment. Source guidance details Comes from guidance...

    Research recommendation
    Published
    26 October 2020

  39. What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?

    recommendation for research, see the rationale section on oral isotretinoin treatment . Full details of the evidence and the committee's...

    Research recommendation
    Published
    3 May 2024

  40. MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)

    NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .

    Medtech innovation briefing
    Published
    11 October 2019

  41. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (IPG772)

    We have moved interventional procedures guidance 772 to become HealthTech guidance 693. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  42. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  43. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

    Safe staffing guideline
    Published
    15 July 2014
    View recommendations

    Sections for SG1

  44. Surveillance strategies: How frequently should surveillance imaging be conducted, and which imaging modality should be used for people with stage IIB to IIIC melanoma?

    recommendation for research, see the rationale and section on follow-up after treatment for melanoma. Full details of the evidence and...

    Research recommendation
    Published
    4 August 2022

  45. Oesophagectomy: What is the effectiveness of endoscopic resection with or without adjuvant chemoradiotherapy and oesophagectomy for adults with T1b oesophageal adenocarcinoma?

    committee's discussion are in evidence review K: oesophagectomy versus endoscopy treatment. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 March 2023

  46. Impact of neonatal infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  47. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    recommendation for research, see the rationale and section on follow-up after treatment for melanoma. Full details of the evidence and...

    Research recommendation
    Published
    4 August 2022

  48. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space

    Medtech innovation briefing
    Published
    2 March 2015

  49. PICO negative pressure wound dressings for closed surgical incisions (HTG509)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    HealthTech guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for HTG509

  50. Blood pressure targets for people aged over 80: What is the optimum blood pressure target for people aged over 80 with treated primary hypertension (with or without cardiovascular disease)?

    the committee's discussion are in the evidence review K: pharmacological treatment in cardiovascular disease . Source guidance details...

    Research recommendation
    Published
    11 April 2022